CN Patent

CN106138080A — 核苷类化合物在制备治疗丙型肝炎病毒(hcv)感染疾病药物的应用

Assigned to Nankai University · Expires 2016-11-23 · 9y expired

What this patent protects

本发明涉及核苷类化合物I和化合物II在制备治疗丙型肝炎病毒(HCV)感染疾病药物的应用，还涉及其各种光学异构体、药学上可接受的盐、溶剂合物以及前药在制备治疗HCV感染疾病药物的应用。本发明还涉及含有式I和式II结构核苷类化合物的药物组合物在制备治疗HCV感染疾病药物的应用。式I和式II所示化合物中R 1 、R 2 、R 3 和AA如说明书所定义。

USPTO Abstract

本发明涉及核苷类化合物I和化合物II在制备治疗丙型肝炎病毒(HCV)感染疾病药物的应用，还涉及其各种光学异构体、药学上可接受的盐、溶剂合物以及前药在制备治疗HCV感染疾病药物的应用。本发明还涉及含有式I和式II结构核苷类化合物的药物组合物在制备治疗HCV感染疾病药物的应用。式I和式II所示化合物中R 1 、R 2 、R 3 和AA如说明书所定义。

Drugs covered by this patent

Patent Metadata

Patent number: CN106138080A
Jurisdiction: CN
Classification: —
Expires: 2016-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Nankai University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.